Kolon TissueGene, Inc.

KOSDAQ:A950160 Stock Report

Market Cap: ₩7.4t

Kolon TissueGene Past Earnings Performance

Past criteria checks 0/6

Kolon TissueGene's earnings have been declining at an average annual rate of -4.5%, while the Biotechs industry saw earnings growing at 22.9% annually. Revenues have been growing at an average rate of 5.6% per year.

Key information

-4.46%

Earnings growth rate

8.45%

EPS growth rate

Biotechs Industry Growth11.70%
Revenue growth rate5.57%
Return on equity-47.44%
Net Margin-1,722.65%
Last Earnings Update30 Sep 2025

Recent past performance updates

No updates

Recent updates

Kolon TissueGene (KOSDAQ:950160) Has Debt But No Earnings; Should You Worry?

Nov 29
Kolon TissueGene (KOSDAQ:950160) Has Debt But No Earnings; Should You Worry?

Is Kolon TissueGene (KOSDAQ:950160) Using Too Much Debt?

Jun 26
Is Kolon TissueGene (KOSDAQ:950160) Using Too Much Debt?

Revenue & Expenses Breakdown

How Kolon TissueGene makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A950160 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 255,077-87,45713,5036,871
30 Jun 255,459-87,10915,4307,150
31 Mar 255,108-35,68714,6207,852
31 Dec 245,073-33,79915,8535,612
30 Sep 245,067-18,89814,8305,733
30 Jun 244,719-17,44314,0085,678
31 Mar 244,421-17,11013,8605,603
31 Dec 233,706-17,22413,6565,635
30 Sep 237,012-15,55314,0535,584
30 Jun 236,043-11,09813,6166,319
31 Mar 239,625-9,49414,0456,936
31 Dec 229,456-11,13614,9417,123
30 Sep 226,226-23,98516,25214,858
30 Jun 226,695-40,56016,64525,535
31 Mar 223,750-46,55616,64828,234
31 Dec 214,003-47,37015,99629,890
30 Sep 214,340-43,40317,65624,191
30 Jun 213,717-39,75623,00114,945
31 Mar 213,174-38,05321,22615,120
31 Dec 203,556-41,78824,26615,724
30 Sep 203,649-42,36625,18215,072
30 Jun 203,416-42,29425,79714,981
31 Mar 203,345-45,80027,54516,988
31 Dec 193,035-49,98924,74919,092
30 Sep 192,598-47,29720,69820,948
30 Jun 193,132-38,42113,48319,908
31 Mar 193,389-35,70812,62418,578
31 Dec 183,785-32,26512,58820,970
30 Sep 185,329-46,34518,50225,910
30 Jun 185,207-51,10318,33730,421
31 Mar 184,262-47,83416,41828,377
31 Dec 173,192-45,43314,11527,513
30 Sep 177,454-21,8205,58923,167
30 Jun 1713,295-12,5884,09122,492
31 Mar 1713,295-9,2623,67519,747
31 Dec 1613,295-2,6223,46013,352
31 Dec 15310-6,2513,7532,288

Quality Earnings: A950160 is currently unprofitable.

Growing Profit Margin: A950160 is currently unprofitable.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A950160 is unprofitable, and losses have increased over the past 5 years at a rate of 4.5% per year.

Accelerating Growth: Unable to compare A950160's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: A950160 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (44.3%).

Return on Equity

High ROE: A950160 has a negative Return on Equity (-47.44%), as it is currently unprofitable.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/02/15 00:49
End of Day Share Price 2026/02/13 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kolon TissueGene, Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Haejoo WiKorea Investment & Securities Co., Ltd.
Wan KuNH Investment & Securities Co., Ltd.